February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
The Lancet Haematology’s February Issue is Live
Feb 7, 2025, 19:19

The Lancet Haematology’s February Issue is Live

The Lancet Haematology posted on LinkedIn:

“February Issue Now Live!

This month, our editorial underscores the urgent need to include pregnant and postpartum individuals in clinical trials. The REVAMP-TT and pilot PARTUM trials on hematological disorders show that inclusive research is not just possible – it’s necessary.

February’s cover, created by Marian F., reflects the groundbreaking pilot PARTUM trial led by Leslie Skeith and colleagues. This innovative study showcases the feasibility of low-dose aspirin for postpartum venous thromboembolism prophylaxis, achieving a recruitment rate six times higher than previous low molecular weight heparin trials.

Is it time for a larger trial to evaluate aspirin in this context? Alexander M. Friedam explores this important question.

This Issue is packed with exciting Research Articles! Sovleplenib Phase 2 Trial: A randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of the novel oral spleen tyrosine kinase inhibitor, sovleplenib, for patients with warm autoimmune hemolytic anemia who have faced therapy failures. (Fengkui Zhang)

Multiple Myeloma Trial: A multicenter, single-arm phase 2 trial evaluating the safety and activity of isatuximab in combination with weekly bortezomib, lenalidomide, and limited dexamethasone for patients with newly diagnosed multiple myeloma ineligible for autologous hematopoietic stem-cell transplantation. (Frida Bugge Askeland)

Long-Term Effects of Erythropoiesis-Stimulating Agents: An observational study assessing the long-term impact on survival and health-related quality of life in patients with lower-risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents. (Hege Gravdahl Garelius)

Additionally, this Issue features clinical practice guidelines from ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases) for the diagnosis and treatment of Burkitt lymphoma, as well as a position statement on the diagnosis and management of acute leukaemia and aggressive lymphomas in pregnancy.

And don’t forget to check out our In Focus articles!

Read the Issue here.”